Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Duane Wampler

Physician Assistant, Surgical Fort Wayne, IN Physician Assistant

NPI 1154312122 CMS profile 11163834

7881 Carnegie Blvd, Fort Wayne, IN 46804

Open in the dashboard

General payments

$5,853

325 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Duane Wampler of Fort Wayne, IN is reported in the CMS Open Payments database as having received $5,853 across 325 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,469 76
2024 General $1,191 72
2023 General $816 37
2022 General $1,208 71
2021 General $1,169 69

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Duane Wampler
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Duane Wampler were reported at $1,469. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Duane Wampler Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,169 $111 $36–$285 $132
2022 $1,208 $126 $44–$350 $149
2023 $816 $137 $47–$355 $160
2024 $1,191 $146 $49–$384 $164
2025 $1,469 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. UCB, Inc. $1,416 74 payments
  2. AbbVie, Inc. $1,083 74 payments
  3. Sun Pharmaceutical Industries Inc. $654 26 payments
  4. Janssen Biotech, Inc. $482 40 payments
  5. Regeneron Healthcare Solutions, Inc. $306 7 payments
  6. E.R. Squibb & Sons, L.L.C. $305 26 payments
  7. Galderma Laboratories, L.P. $271 10 payments
  8. Genzyme Corporation $269 11 payments
  9. Lilly USA, LLC $171 10 payments
  10. Pfizer Inc. $139 8 payments
  11. Other $756 39 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,399 319 payments
  2. Education $454 6 payments
Products named General payments · program years 2021–2025
  1. Bimzelx $774 35 payments
  2. Cimzia $642 39 payments
  3. TREMFYA $443 37 payments
  4. RINVOQ $379 27 payments
  5. SKYRIZI $314 24 payments
  6. DUPIXENT Inflammation And Immunology $306 7 payments
  7. SOTYKTU $305 26 payments
  8. DUPIXENT Immunology $295 13 payments
  9. NEMLUVIO $254 9 payments
  10. ILUMYA $249 19 payments
  11. Other $1,725 104 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,651

Median for Physician Assistant: 241

Drug cost

$212,156

Median for Physician Assistant: $4,110

Branded share of claims

4.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 38 $160,982
Fluocinonide Generic 226 $9,522
Fluorouracil Generic 108 $9,027
Clobetasol Propionate Generic 108 $5,229
Ketoconazole Generic 232 $3,983
Triamcinolone Acetonide Generic 282 $3,609
Tacrolimus Generic 25 $3,291
Minocycline Hcl Generic 126 $2,902
Metronidazole Generic 45 $2,106
Dapsone Generic 18 $1,837

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$182,258

Of which drugs: $42,758

Medicare patients

823

Average age 74

Services billed

4,656

394 women, 429 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 45%
Ischemic heart disease 27%
Diabetes 24%
Chronic kidney disease 18%
Depression 17%
Atrial fibrillation 15%
COPD 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 12 32 $166
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 13 113 $82

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Bimzelx
  • UCB, Inc. $414
$414 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $172
$172 — —
RINVOQ
  • AbbVie, Inc. $125
$125 — —
SKYRIZI
  • AbbVie, Inc. $112
$112 — —
ACTHAR
  • Mallinckrodt Hospital Products Inc. $61
$61 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

325 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record